Skip to main content

Table 2 Cox uni- and multivariate analysis of recurrence free and overall survival according to RBM3 mRNA levels (Cohort I) and protein expression (Cohort II)

From: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer

  Recurrence free survival    Overall survival   
   HR (95% CI)   p-value   HR (95% CI)   p-value
Cohort I         
    Univariate     Univariate  
low (n = 115, nevent = 85) 1.00    (n = 115, nevent = 54) 1.00   
high (n = 142, nevent = 89) 0.64 (0.47-0.86)   0.003 (n = 139, nevent = 50) 0.64 (0.44-0.95)   0.024
    Multivariate     Multivariate  
low (n = 103, nevent = 77) 1.00    (n = 103, nevent = 51) 1.00   
high (n = 119, nevent = 71) 0.61 (0.44-0.84)   0.003 (n = 117, nevent = 50) 0.62 (0.41-0.95)   0.028
Cohort II         
        Univariate  
negative x x x x (n = 74, nevent = 33) 1.00   
positive x x x x (n = 77, nevent = 44) 0.53 (0.35-0.79)   0.002
        Multivariate  
negative x x x x (n = 68, nevent = 29) 1.00   
positive x x x x (n = 71, nevent = 42) 0.61 (0.40-0.92)   0.017
  1. Multivariate analysis included adjustment for age (continuous) stage (I-II vs III-IV), grade (I-II vs III) and residual disease (none vs any, only available for Cohort I).